Cell Death & Disease-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2173941, encodeId=78ad21e3941c3, content=偏重的研究方向：心血管 经验分享：请大家留言说说一审多久啊，着急毕业，麻烦啦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=97525587163, createdName=ms6000000973811944, createdTime=Sat Dec 09 23:54:03 CST 2023, time=2023-12-09, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2198868, encodeId=84d9219886842, content=前往app查看评论内容, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Tue Apr 16 23:30:16 CST 2024, time=1小时前, status=0, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2124046, encodeId=6a3121240465b, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：从CDD转投过来的，投稿后3天状态变成under consideration，等待3周未分配编辑，催稿了一次，回复目前稿件太多，第29天分配编辑，然后出现Zip of files for Reviewer，目前仍是under consideration，过来沾沾各位大神的运气~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e6f2450981, createdName=123f51aam86(暂无昵称), createdTime=Thu Apr 06 10:11:01 CST 2023, time=2023-04-06, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2195207, encodeId=bf68219520e47, content=偏重的研究方向：肿瘤 经验分享：小cdd好还是cancer letters好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Mon Mar 25 13:13:11 CST 2024, time=2024-03-25, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2196205, encodeId=f8ea2196205f2, content=偏重的研究方向：免疫;细胞死亡 经验分享：我的Under Consideration 6天就直接Decision Made，这种情况是被拒了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=313a5603215, createdName=ms3000002118315862, createdTime=Sat Mar 30 11:00:33 CST 2024, time=2024-03-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2108140, encodeId=f9532108140cb, content=投稿7天 decision made ，现在12天了，not assigned，未收到邮件，是不是拒了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5285325183, createdName=148b8e1fm60暂无昵称, createdTime=Fri Dec 30 13:11:59 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174840, encodeId=c6b921e48403a, content=偏重的研究方向：肿瘤 经验分享：刚submit，沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4d02501413, createdName=沧海医僧笑, createdTime=Thu Dec 14 01:51:31 CST 2023, time=2023-12-14, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向：肿瘤 经验分享：提交10天，显示状态为Decision made什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡 经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省)]

2023-12-09 ms6000000973811944 来自辽宁省

偏重的研究方向：心血管
经验分享：请大家留言说说一审多久啊，着急毕业，麻烦啦

40 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2173941, encodeId=78ad21e3941c3, content=偏重的研究方向：心血管 经验分享：请大家留言说说一审多久啊，着急毕业，麻烦啦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=97525587163, createdName=ms6000000973811944, createdTime=Sat Dec 09 23:54:03 CST 2023, time=2023-12-09, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2198868, encodeId=84d9219886842, content=前往app查看评论内容, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Tue Apr 16 23:30:16 CST 2024, time=1小时前, status=0, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2124046, encodeId=6a3121240465b, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：从CDD转投过来的，投稿后3天状态变成under consideration，等待3周未分配编辑，催稿了一次，回复目前稿件太多，第29天分配编辑，然后出现Zip of files for Reviewer，目前仍是under consideration，过来沾沾各位大神的运气~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e6f2450981, createdName=123f51aam86(暂无昵称), createdTime=Thu Apr 06 10:11:01 CST 2023, time=2023-04-06, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2195207, encodeId=bf68219520e47, content=偏重的研究方向：肿瘤 经验分享：小cdd好还是cancer letters好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Mon Mar 25 13:13:11 CST 2024, time=2024-03-25, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2196205, encodeId=f8ea2196205f2, content=偏重的研究方向：免疫;细胞死亡 经验分享：我的Under Consideration 6天就直接Decision Made，这种情况是被拒了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=313a5603215, createdName=ms3000002118315862, createdTime=Sat Mar 30 11:00:33 CST 2024, time=2024-03-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2108140, encodeId=f9532108140cb, content=投稿7天 decision made ，现在12天了，not assigned，未收到邮件，是不是拒了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5285325183, createdName=148b8e1fm60暂无昵称, createdTime=Fri Dec 30 13:11:59 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174840, encodeId=c6b921e48403a, content=偏重的研究方向：肿瘤 经验分享：刚submit，沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4d02501413, createdName=沧海医僧笑, createdTime=Thu Dec 14 01:51:31 CST 2023, time=2023-12-14, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向：肿瘤 经验分享：提交10天，显示状态为Decision made什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡 经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省)]

1小时前 Judy Bright 来自广东省

前往app查看评论内容

0 0

[GetPortalCommentsPageByObjectIdResponse(id=2173941, encodeId=78ad21e3941c3, content=偏重的研究方向：心血管 经验分享：请大家留言说说一审多久啊，着急毕业，麻烦啦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=97525587163, createdName=ms6000000973811944, createdTime=Sat Dec 09 23:54:03 CST 2023, time=2023-12-09, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2198868, encodeId=84d9219886842, content=前往app查看评论内容, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Tue Apr 16 23:30:16 CST 2024, time=1小时前, status=0, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2124046, encodeId=6a3121240465b, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：从CDD转投过来的，投稿后3天状态变成under consideration，等待3周未分配编辑，催稿了一次，回复目前稿件太多，第29天分配编辑，然后出现Zip of files for Reviewer，目前仍是under consideration，过来沾沾各位大神的运气~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e6f2450981, createdName=123f51aam86(暂无昵称), createdTime=Thu Apr 06 10:11:01 CST 2023, time=2023-04-06, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2195207, encodeId=bf68219520e47, content=偏重的研究方向：肿瘤 经验分享：小cdd好还是cancer letters好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Mon Mar 25 13:13:11 CST 2024, time=2024-03-25, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2196205, encodeId=f8ea2196205f2, content=偏重的研究方向：免疫;细胞死亡 经验分享：我的Under Consideration 6天就直接Decision Made，这种情况是被拒了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=313a5603215, createdName=ms3000002118315862, createdTime=Sat Mar 30 11:00:33 CST 2024, time=2024-03-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2108140, encodeId=f9532108140cb, content=投稿7天 decision made ，现在12天了，not assigned，未收到邮件，是不是拒了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5285325183, createdName=148b8e1fm60暂无昵称, createdTime=Fri Dec 30 13:11:59 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174840, encodeId=c6b921e48403a, content=偏重的研究方向：肿瘤 经验分享：刚submit，沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4d02501413, createdName=沧海医僧笑, createdTime=Thu Dec 14 01:51:31 CST 2023, time=2023-12-14, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向：肿瘤 经验分享：提交10天，显示状态为Decision made什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡 经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省)]

2023-04-06 123f51aam86(暂无昵称) 来自陕西省

审稿速度:3.0 | 投稿命中率:50.0
经验分享：从CDD转投过来的，投稿后3天状态变成under consideration，等待3周未分配编辑，催稿了一次，回复目前稿件太多，第29天分配编辑，然后出现Zip of files for Reviewer，目前仍是under consideration，过来沾沾各位大神的运气~

143 23

展开23条回复

[GetPortalCommentsPageByObjectIdResponse(id=2173941, encodeId=78ad21e3941c3, content=偏重的研究方向：心血管 经验分享：请大家留言说说一审多久啊，着急毕业，麻烦啦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=97525587163, createdName=ms6000000973811944, createdTime=Sat Dec 09 23:54:03 CST 2023, time=2023-12-09, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2198868, encodeId=84d9219886842, content=前往app查看评论内容, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Tue Apr 16 23:30:16 CST 2024, time=1小时前, status=0, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2124046, encodeId=6a3121240465b, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：从CDD转投过来的，投稿后3天状态变成under consideration，等待3周未分配编辑，催稿了一次，回复目前稿件太多，第29天分配编辑，然后出现Zip of files for Reviewer，目前仍是under consideration，过来沾沾各位大神的运气~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e6f2450981, createdName=123f51aam86(暂无昵称), createdTime=Thu Apr 06 10:11:01 CST 2023, time=2023-04-06, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2195207, encodeId=bf68219520e47, content=偏重的研究方向：肿瘤 经验分享：小cdd好还是cancer letters好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Mon Mar 25 13:13:11 CST 2024, time=2024-03-25, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2196205, encodeId=f8ea2196205f2, content=偏重的研究方向：免疫;细胞死亡 经验分享：我的Under Consideration 6天就直接Decision Made，这种情况是被拒了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=313a5603215, createdName=ms3000002118315862, createdTime=Sat Mar 30 11:00:33 CST 2024, time=2024-03-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2108140, encodeId=f9532108140cb, content=投稿7天 decision made ，现在12天了，not assigned，未收到邮件，是不是拒了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5285325183, createdName=148b8e1fm60暂无昵称, createdTime=Fri Dec 30 13:11:59 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174840, encodeId=c6b921e48403a, content=偏重的研究方向：肿瘤 经验分享：刚submit，沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4d02501413, createdName=沧海医僧笑, createdTime=Thu Dec 14 01:51:31 CST 2023, time=2023-12-14, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向：肿瘤 经验分享：提交10天，显示状态为Decision made什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡 经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省)]

2024-03-25 124a8810m95(暂无昵称) 来自重庆

偏重的研究方向：肿瘤
经验分享：小cdd好还是cancer letters好？

10 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2173941, encodeId=78ad21e3941c3, content=偏重的研究方向：心血管 经验分享：请大家留言说说一审多久啊，着急毕业，麻烦啦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=97525587163, createdName=ms6000000973811944, createdTime=Sat Dec 09 23:54:03 CST 2023, time=2023-12-09, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2198868, encodeId=84d9219886842, content=前往app查看评论内容, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Tue Apr 16 23:30:16 CST 2024, time=1小时前, status=0, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2124046, encodeId=6a3121240465b, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：从CDD转投过来的，投稿后3天状态变成under consideration，等待3周未分配编辑，催稿了一次，回复目前稿件太多，第29天分配编辑，然后出现Zip of files for Reviewer，目前仍是under consideration，过来沾沾各位大神的运气~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e6f2450981, createdName=123f51aam86(暂无昵称), createdTime=Thu Apr 06 10:11:01 CST 2023, time=2023-04-06, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2195207, encodeId=bf68219520e47, content=偏重的研究方向：肿瘤 经验分享：小cdd好还是cancer letters好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Mon Mar 25 13:13:11 CST 2024, time=2024-03-25, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2196205, encodeId=f8ea2196205f2, content=偏重的研究方向：免疫;细胞死亡 经验分享：我的Under Consideration 6天就直接Decision Made，这种情况是被拒了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=313a5603215, createdName=ms3000002118315862, createdTime=Sat Mar 30 11:00:33 CST 2024, time=2024-03-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2108140, encodeId=f9532108140cb, content=投稿7天 decision made ，现在12天了，not assigned，未收到邮件，是不是拒了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5285325183, createdName=148b8e1fm60暂无昵称, createdTime=Fri Dec 30 13:11:59 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174840, encodeId=c6b921e48403a, content=偏重的研究方向：肿瘤 经验分享：刚submit，沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4d02501413, createdName=沧海医僧笑, createdTime=Thu Dec 14 01:51:31 CST 2023, time=2023-12-14, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向：肿瘤 经验分享：提交10天，显示状态为Decision made什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡 经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省)]

2024-03-30 ms3000002118315862 来自广东省

偏重的研究方向：免疫;细胞死亡
经验分享：我的Under Consideration 6天就直接Decision Made，这种情况是被拒了吗

7 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2173941, encodeId=78ad21e3941c3, content=偏重的研究方向：心血管 经验分享：请大家留言说说一审多久啊，着急毕业，麻烦啦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=97525587163, createdName=ms6000000973811944, createdTime=Sat Dec 09 23:54:03 CST 2023, time=2023-12-09, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2198868, encodeId=84d9219886842, content=前往app查看评论内容, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Tue Apr 16 23:30:16 CST 2024, time=1小时前, status=0, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2124046, encodeId=6a3121240465b, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：从CDD转投过来的，投稿后3天状态变成under consideration，等待3周未分配编辑，催稿了一次，回复目前稿件太多，第29天分配编辑，然后出现Zip of files for Reviewer，目前仍是under consideration，过来沾沾各位大神的运气~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e6f2450981, createdName=123f51aam86(暂无昵称), createdTime=Thu Apr 06 10:11:01 CST 2023, time=2023-04-06, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2195207, encodeId=bf68219520e47, content=偏重的研究方向：肿瘤 经验分享：小cdd好还是cancer letters好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Mon Mar 25 13:13:11 CST 2024, time=2024-03-25, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2196205, encodeId=f8ea2196205f2, content=偏重的研究方向：免疫;细胞死亡 经验分享：我的Under Consideration 6天就直接Decision Made，这种情况是被拒了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=313a5603215, createdName=ms3000002118315862, createdTime=Sat Mar 30 11:00:33 CST 2024, time=2024-03-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2108140, encodeId=f9532108140cb, content=投稿7天 decision made ，现在12天了，not assigned，未收到邮件，是不是拒了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5285325183, createdName=148b8e1fm60暂无昵称, createdTime=Fri Dec 30 13:11:59 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174840, encodeId=c6b921e48403a, content=偏重的研究方向：肿瘤 经验分享：刚submit，沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4d02501413, createdName=沧海医僧笑, createdTime=Thu Dec 14 01:51:31 CST 2023, time=2023-12-14, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向：肿瘤 经验分享：提交10天，显示状态为Decision made什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡 经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省)]

2022-12-30 148b8e1fm60暂无昵称

投稿7天 decision made ，现在12天了，not assigned，未收到邮件，是不是拒了？

55 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2173941, encodeId=78ad21e3941c3, content=偏重的研究方向：心血管 经验分享：请大家留言说说一审多久啊，着急毕业，麻烦啦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=97525587163, createdName=ms6000000973811944, createdTime=Sat Dec 09 23:54:03 CST 2023, time=2023-12-09, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2198868, encodeId=84d9219886842, content=前往app查看评论内容, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Tue Apr 16 23:30:16 CST 2024, time=1小时前, status=0, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2124046, encodeId=6a3121240465b, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：从CDD转投过来的，投稿后3天状态变成under consideration，等待3周未分配编辑，催稿了一次，回复目前稿件太多，第29天分配编辑，然后出现Zip of files for Reviewer，目前仍是under consideration，过来沾沾各位大神的运气~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e6f2450981, createdName=123f51aam86(暂无昵称), createdTime=Thu Apr 06 10:11:01 CST 2023, time=2023-04-06, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2195207, encodeId=bf68219520e47, content=偏重的研究方向：肿瘤 经验分享：小cdd好还是cancer letters好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Mon Mar 25 13:13:11 CST 2024, time=2024-03-25, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2196205, encodeId=f8ea2196205f2, content=偏重的研究方向：免疫;细胞死亡 经验分享：我的Under Consideration 6天就直接Decision Made，这种情况是被拒了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=313a5603215, createdName=ms3000002118315862, createdTime=Sat Mar 30 11:00:33 CST 2024, time=2024-03-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2108140, encodeId=f9532108140cb, content=投稿7天 decision made ，现在12天了，not assigned，未收到邮件，是不是拒了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5285325183, createdName=148b8e1fm60暂无昵称, createdTime=Fri Dec 30 13:11:59 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174840, encodeId=c6b921e48403a, content=偏重的研究方向：肿瘤 经验分享：刚submit，沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4d02501413, createdName=沧海医僧笑, createdTime=Thu Dec 14 01:51:31 CST 2023, time=2023-12-14, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向：肿瘤 经验分享：提交10天，显示状态为Decision made什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡 经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省)]

2023-12-14 沧海医僧笑来自重庆

偏重的研究方向：肿瘤
经验分享：刚submit，沾沾大家的喜气

46 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2173941, encodeId=78ad21e3941c3, content=偏重的研究方向：心血管 经验分享：请大家留言说说一审多久啊，着急毕业，麻烦啦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=97525587163, createdName=ms6000000973811944, createdTime=Sat Dec 09 23:54:03 CST 2023, time=2023-12-09, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2198868, encodeId=84d9219886842, content=前往app查看评论内容, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Tue Apr 16 23:30:16 CST 2024, time=1小时前, status=0, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2124046, encodeId=6a3121240465b, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：从CDD转投过来的，投稿后3天状态变成under consideration，等待3周未分配编辑，催稿了一次，回复目前稿件太多，第29天分配编辑，然后出现Zip of files for Reviewer，目前仍是under consideration，过来沾沾各位大神的运气~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e6f2450981, createdName=123f51aam86(暂无昵称), createdTime=Thu Apr 06 10:11:01 CST 2023, time=2023-04-06, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2195207, encodeId=bf68219520e47, content=偏重的研究方向：肿瘤 经验分享：小cdd好还是cancer letters好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Mon Mar 25 13:13:11 CST 2024, time=2024-03-25, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2196205, encodeId=f8ea2196205f2, content=偏重的研究方向：免疫;细胞死亡 经验分享：我的Under Consideration 6天就直接Decision Made，这种情况是被拒了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=313a5603215, createdName=ms3000002118315862, createdTime=Sat Mar 30 11:00:33 CST 2024, time=2024-03-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2108140, encodeId=f9532108140cb, content=投稿7天 decision made ，现在12天了，not assigned，未收到邮件，是不是拒了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5285325183, createdName=148b8e1fm60暂无昵称, createdTime=Fri Dec 30 13:11:59 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174840, encodeId=c6b921e48403a, content=偏重的研究方向：肿瘤 经验分享：刚submit，沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4d02501413, createdName=沧海医僧笑, createdTime=Thu Dec 14 01:51:31 CST 2023, time=2023-12-14, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向：肿瘤 经验分享：提交10天，显示状态为Decision made什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡 经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省)]

2023-08-25 1245a556m23暂无昵称来自河南省

从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？

71 17

展开17条回复

[GetPortalCommentsPageByObjectIdResponse(id=2173941, encodeId=78ad21e3941c3, content=偏重的研究方向：心血管 经验分享：请大家留言说说一审多久啊，着急毕业，麻烦啦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=97525587163, createdName=ms6000000973811944, createdTime=Sat Dec 09 23:54:03 CST 2023, time=2023-12-09, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2198868, encodeId=84d9219886842, content=前往app查看评论内容, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Tue Apr 16 23:30:16 CST 2024, time=1小时前, status=0, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2124046, encodeId=6a3121240465b, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：从CDD转投过来的，投稿后3天状态变成under consideration，等待3周未分配编辑，催稿了一次，回复目前稿件太多，第29天分配编辑，然后出现Zip of files for Reviewer，目前仍是under consideration，过来沾沾各位大神的运气~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e6f2450981, createdName=123f51aam86(暂无昵称), createdTime=Thu Apr 06 10:11:01 CST 2023, time=2023-04-06, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2195207, encodeId=bf68219520e47, content=偏重的研究方向：肿瘤 经验分享：小cdd好还是cancer letters好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Mon Mar 25 13:13:11 CST 2024, time=2024-03-25, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2196205, encodeId=f8ea2196205f2, content=偏重的研究方向：免疫;细胞死亡 经验分享：我的Under Consideration 6天就直接Decision Made，这种情况是被拒了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=313a5603215, createdName=ms3000002118315862, createdTime=Sat Mar 30 11:00:33 CST 2024, time=2024-03-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2108140, encodeId=f9532108140cb, content=投稿7天 decision made ，现在12天了，not assigned，未收到邮件，是不是拒了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5285325183, createdName=148b8e1fm60暂无昵称, createdTime=Fri Dec 30 13:11:59 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174840, encodeId=c6b921e48403a, content=偏重的研究方向：肿瘤 经验分享：刚submit，沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4d02501413, createdName=沧海医僧笑, createdTime=Thu Dec 14 01:51:31 CST 2023, time=2023-12-14, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向：肿瘤 经验分享：提交10天，显示状态为Decision made什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡 经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省)]

2024-01-16 ms4000000731438466 来自天津

偏重的研究方向：肿瘤
经验分享：提交10天，显示状态为Decision made什么情况？

40 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2173941, encodeId=78ad21e3941c3, content=偏重的研究方向：心血管 经验分享：请大家留言说说一审多久啊，着急毕业，麻烦啦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=97525587163, createdName=ms6000000973811944, createdTime=Sat Dec 09 23:54:03 CST 2023, time=2023-12-09, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2198868, encodeId=84d9219886842, content=前往app查看评论内容, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Tue Apr 16 23:30:16 CST 2024, time=1小时前, status=0, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2124046, encodeId=6a3121240465b, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：从CDD转投过来的，投稿后3天状态变成under consideration，等待3周未分配编辑，催稿了一次，回复目前稿件太多，第29天分配编辑，然后出现Zip of files for Reviewer，目前仍是under consideration，过来沾沾各位大神的运气~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e6f2450981, createdName=123f51aam86(暂无昵称), createdTime=Thu Apr 06 10:11:01 CST 2023, time=2023-04-06, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2195207, encodeId=bf68219520e47, content=偏重的研究方向：肿瘤 经验分享：小cdd好还是cancer letters好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Mon Mar 25 13:13:11 CST 2024, time=2024-03-25, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2196205, encodeId=f8ea2196205f2, content=偏重的研究方向：免疫;细胞死亡 经验分享：我的Under Consideration 6天就直接Decision Made，这种情况是被拒了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=313a5603215, createdName=ms3000002118315862, createdTime=Sat Mar 30 11:00:33 CST 2024, time=2024-03-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2108140, encodeId=f9532108140cb, content=投稿7天 decision made ，现在12天了，not assigned，未收到邮件，是不是拒了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5285325183, createdName=148b8e1fm60暂无昵称, createdTime=Fri Dec 30 13:11:59 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174840, encodeId=c6b921e48403a, content=偏重的研究方向：肿瘤 经验分享：刚submit，沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4d02501413, createdName=沧海医僧笑, createdTime=Thu Dec 14 01:51:31 CST 2023, time=2023-12-14, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向：肿瘤 经验分享：提交10天，显示状态为Decision made什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡 经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省)]

2023-05-18 36192448 来自湖南省

偏重的研究方向：细胞死亡
经验分享：一审65天了，还没消息，彻底躺平了

76 12

展开12条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务